Rosiglitazone Ameliorates Endotoxin-Induced Organ Damage in Conscious Rats

Abstract

Rosiglitazone is a peroxisome proliferator-activated receptor (PPAR)-γ agonist. By inhibiting nuclear factor κB (NF-κB), it decreases tumor necrosis factor-α (TNF-α) and interleukin 6 (IL-6) and has an anti-inflammatory effect. Endotoxin shock can induce the production of several inflammatory mediators such as TNF-α and IL-6, leading to multiple organ dysfunction and death. We investigated the effects of rosiglitazone (.3 mg/kg, intravenous administration) on the physiologic attributes and cytokine levels in endotoxin shock in conscious rats. Endotoxin shock was induced by intravenous injection of Klebsiella pneumoniae lipopolysaccharides (LPSs; 10 mg/kg) in conscious rats. Mean arterial pressure (MAP) and heart rate (HR) were continuously monitored for 24 hr after LPS administration. Levels of biochemical and cytokine parameters, including glutamic oxaloacetic transaminase (GOT), glutamic pyruvic transaminase (GPT), blood urea nitrogen (BUN), creatinine (Cre), lactic dehydrogenase (LDH), creatine phosphokinase (CPK), glucose, TNF-α, and IL-6 were measured at 0, 1, 3, 6, 12, and 24 hr after sepsis. Endotoxin shock significantly increased blood GOT, GPT, BUN, Cre, LDH, CPK, glucose, TNF-α, and IL-6 levels and HR, while also decreasing MAP. Rosiglitazone diminished the increase in HR, decreased the markers of organ injury (GOT, GPT, BUN, Cre, LDH, CPK, glucose) and inflammatory biomarkers (TNF-α, IL-6), and did not affect MAP after LPS. In conclusion, rosiglitazone ameliorated endotoxin shock-induced markers of organ injury and suppressed the release of TNF-α and IL-6 in conscious rats.

Keywords

endotoxin shock rosiglitazone conscious rat

Get full access to this article

View all access options for this article.

References

Angus, D.C. , Linde-Zwirble, W.T. , Lidicker, J. , Clermont, G. , Carcillo, J. , & Pinsky, M.R. ( 2001). Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Critical Care Medicine, 29, 1303-1310.

Ayala, A. , Lomas, J.L. , Grutkoski, P.S. , & Chung, C.S. ( 2003). Pathological aspects of apoptosis in severe sepsis and shock? The International Journal of Biochemistry & Cell Biology, 35, 7-15.

Cuzzocrea, S. , Pisano, B. , Dugo, L. , Ianaro, A. , Patel, N.S.A. , Di Paola, R. , et al. (2004). Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-γ, reduces the development of non-septic shock induced by zymosan in mice. Critical Care Medicine, 32, 457-466.

Hannele, Y.J. (2004). Drug therapy: Thiazolidinediones . The New England Journal of Medicine, 351, 1106-1108.

Haveman, J.W. , Muller Kobold, A.C. , Tervaert, J.W. , van den Berg , A.P. , Tulleken, J.E. , Kallenberg, C.G. , et al. ( 1999). The central role of monocytes in the pathogenesis of sepsis: Consequences for immunomonitoring and treatment. The Netherlands Journal of Medicine, 55, 132-141.

Hsu, B.G. , Lee, R.P. , Yang, F.L. , Harn, H.J. , & Chen, H.I. (2006). Post-treatment with N-acetylcysteine ameliorates the endotoxin shock-induced organ damage in conscious rats. Life Sciences, 79, 2010-2016.

Hsu, B.G. , Yang, F.L. , Lee, R.P. , Peng, T.C. , & Chen, H.I. (2005). Posttreatment with low dose propofol on inflammation responses to lipopolysaccharide-induced shock in conscious rats. Clinical and Experimental Pharmacology and Physiology, 32, 24-29.

Jiang, C. , Ting, A.T. , & Seed, B. ( 1998). PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature, 391, 82-86.

Kuboki, S. , Shin, T. , Huber, N. , Eismann, T. , Galloway, E. , Schuster, R. , et al. (2008). Peroxisome proliferator-activated receptor-gamma protects against hepatic ischemia/reperfusion injury in mice. Hepatology, 47, 215-224.

10.

Lee, S. , Kim, W. , Kang, K.P. , Moon, S.O. , Sung, M.J. , Kim, D.H. , et al. (2005). Agonist of peroxisome proliferator-activated receptor-gamma, rosiglitazone, reduces renal injury and dysfunction in a murine sepsis model. Nephrology, Dialysis, Transplantation, 20, 1057-1065.

11.

Lehmann, J.M. , Moore, L.B. , Smith-Oliver , T.A. , Wilkison, W.O. , Willson, T.M. , & Kliewer, S.A. (1995). An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator activated receptor gamma (PPAR-γ). The Journal of Biological Chemistry, 270, 12953-12956.

12.

Liu, D. , Zeng, B.X. , Zhang, S.H. , Wang, Y.L. , Zeng, L. , Geng, Z.L. , et al. (2005). Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, reduces acute lung injury in endotoxemic rats. Critical Care Medicine, 33, 2309-2316.

13.

Marik, P.E. , & Raghavan, M. (2004). Stress-hyperglycemia, insulin and immunomodulation in sepsis. Intensive Care Medicine , 30, 748-756.

14.

Mayeux, P.R. (1997). Pathobiology of lipopolysaccharide . Journal of Toxicology and Environmental Health, 51, 415-435.

15.

McCowen, K.C. , Malhotra, A. , & Bistrian , B.R. (2001). Stress-induced hyperglycemia. Critical Care Clinics, 17, 107-124.

16.

Oberholzer, A. , Oberholzer, C. , & Moldawer , L.L. (2001). Sepsis syndromes: Understanding the role of innate and acquired immunity. Shock, 16, 83-96.

17.

Ricote, M. , Li, A.C. , Willson, T.M. , Kelly, C.J. , & Glass, C.K. ( 1998). The peroxisome proliferator activated receptor gamma is a negative regulator of macrophage activation. Nature, 391, 79-82.

18.

Riedemann, N.C. , Guo, R.F. , & Ward, P.A. (2003). Novel strategies for the treatment of sepsis. Nature Medicine, 9, 517-524.

19.

Senftleben, U. , & Karin, M. (2002). The IKK/NF-kappaB pathway . Critical Care Medicine, 30, S18-S26.

20.

Siddiqui, A.M. , Cui, X. , Wu, R. , Dong, W. , Zhou, M. , Hu, M. , et al. (2006). The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-. Critical Care Medicine, 34, 1874-1882.

21.

Vanhorebeek, I. , Langouche, L. , & Van den Berghe , G. (2007). Tight blood glucose control: What is the evidence? Critical Care Medicine, 35, S496-S502.

22.

Wagstaff, A.J. , & Goa, K.L. (2002). Rosiglitazone: A review of its use in the management of type 2 diabetes mellitus. Drugs, 62, 1805-1837.

23.

Yue, Tl. TL. , Chen, J. , Bao, W. , Narayanan, P.K. , Bril, A. , Jiang, W. , et al. (2001). In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation, 104, 2588-2594.

24.

Zhou, M. , Wu, R. , Dong, W. , Jacob, A. , & Wang, P. ( 2008). Endotoxin downregulates peroxisome proliferator-activated receptor-gamma via the increase in TNF-alpha release. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology , 294, R84-R92.

25.

Zingarelli, B. , & Cook, J.A. (2005). Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. Shock, 23, 393-399.